IGMS

1.16

5.69% -0.07

Dopo l'orario di chiusura: 1.15 -0.01 -0.86%

Igm Biosciences Inc (IGMS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$1.23

Aprire:

$1.19

Volume 24 ore:

109.91K

Relative Volume:

0.25

Capitalizzazione di mercato:

$70.24M

Reddito:

$2.91M

Utile/perdita netta:

$-220.40M

Rapporto P/E:

-0.3187

EPS:

-3.64

Flusso di cassa netto:

$-176.15M

1 W Prestazione:

-9.38%

1M Prestazione:

-7.94%

6M Prestazione:

-92.21%

1 anno Prestazione:

-87.15%

Intervallo 1D:

$1.1374

$1.23

Intervallo di 1 settimana:

$1.11

$1.30

Portata 52W:

$1.11

$22.50

Igm Biosciences Inc Stock (IGMS) Company Profile

Nome

Igm Biosciences Inc

Settore

Healthcare (1182)

Industria

Biotechnology (678)

Telefono

650-965-7873

Indirizzo

325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW

Dipendente

Cinguettio

Prossima data di guadagno

2025-03-31

Ultimi documenti SEC

IGMS's Discussions on Twitter

Confronta IGMS con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
IGMS Igm Biosciences Inc	1.16	70.24M	2.91M	-220.40M	-176.15M	-3.64
VRTX Vertex Pharmaceuticals Inc	484.01	125.55B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	610.64	67.78B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	590.06	36.24B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	262.16	33.99B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	264.32	28.77B	3.81B	-644.79M	-669.77M	-6.24

Igm Biosciences Inc Stock (IGMS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-01-10	Downgrade	BMO Capital Markets	Outperform → Market Perform
2025-01-10	Downgrade	Guggenheim	Buy → Neutral
2025-01-10	Downgrade	Morgan Stanley	Equal-Weight → Underweight
2025-01-10	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2025-01-10	Downgrade	Stifel	Buy → Hold
2024-12-06	Iniziato	BMO Capital Markets	Outperform
2024-10-01	Downgrade	JP Morgan	Neutral → Underweight
2024-10-01	Downgrade	Truist	Buy → Hold
2024-02-09	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2023-12-15	Downgrade	BofA Securities	Buy → Neutral
2023-12-07	Downgrade	H.C. Wainwright	Buy → Neutral
2022-11-09	Ripresa	Jefferies	Buy
2022-10-17	Iniziato	JP Morgan	Neutral
2022-08-29	Iniziato	BofA Securities	Buy
2021-12-13	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2021-11-05	Aggiornamento	Wedbush	Neutral → Outperform
2021-08-26	Iniziato	Morgan Stanley	Overweight
2021-01-29	Iniziato	RBC Capital Mkts	Outperform
2021-01-19	Reiterato	H.C. Wainwright	Buy
2020-12-22	Downgrade	Wedbush	Outperform → Neutral
2020-07-17	Iniziato	Robert W. Baird	Outperform
2020-07-01	Iniziato	H.C. Wainwright	Buy
2020-05-28	Iniziato	SunTrust	Buy
2020-04-22	Iniziato	Wedbush	Outperform
2019-10-14	Iniziato	Guggenheim	Buy
2019-10-14	Iniziato	Jefferies	Buy
2019-10-14	Iniziato	Piper Jaffray	Overweight
2019-10-14	Iniziato	Stifel	Buy

Mostra tutto

Igm Biosciences Inc Borsa (IGMS) Ultime notizie

03:44 AM

Short Interest in IGM Biosciences, Inc. (NASDAQ:IGMS) Decreases By 19.3% - MarketBeat

03:44 AM

Apr 02, 2025

IGMS STOCK ALERT: Levi & Korsinsky Notifies IGM Biosciences, Inc. Investors of an Ongoing Investigation - ACCESS Newswire

Apr 02, 2025

Mar 31, 2025

IGMS stock plunges to 52-week low at $1.14 amid market challenges By Investing.com - Investing.com South Africa

Mar 31, 2025

Charles Schwab Investment Management Inc. Buys 9,441 Shares of IGM Biosciences, Inc. (NASDAQ:IGMS) - Defense World

Mar 31, 2025

IGMS stock plunges to 52-week low at $1.14 amid market challenges - Investing.com

Mar 31, 2025

Mar 29, 2025

IGM Biosciences (NASDAQ:IGMS) Shares Up 5.9%What's Next? - MarketBeat

Mar 29, 2025

Mar 28, 2025

IGM Biosciences stock plunges to 52-week low of $1.59 - MSN

Mar 28, 2025

IGM Biosciences, Inc. (NASDAQ:IGMS) Given Average Rating of "Reduce" by Brokerages - MarketBeat

Mar 28, 2025

IGM Biosciences, Inc. (NASDAQ:IGMS) Receives $5.50 Consensus PT from Brokerages - Defense World

Mar 28, 2025

Mar 25, 2025

IGM Biosciences (NASDAQ:IGMS) Shares Up 5.9% – Here’s Why - Defense World

Mar 25, 2025

Mar 19, 2025

IGM Biosciences CEO Mary Beth Harler sells $9,014 in stock By Investing.com - Investing.com Australia

Mar 19, 2025

Mar 18, 2025

IGM Biosciences CFO Tahir Misbah sells shares worth $9,014 By Investing.com - Investing.com South Africa

Mar 18, 2025

IGM Biosciences chief business officer sells $5,549 in stock By Investing.com - Investing.com South Africa

Mar 18, 2025

IGM Biosciences CEO Mary Beth Harler sells $9,014 in stock - Investing.com India

Mar 18, 2025

IGM Biosciences chief business officer sells $5,549 in stock - Investing.com India

Mar 18, 2025

IGM Biosciences CFO Tahir Misbah sells shares worth $9,014 - Investing.com India

Mar 18, 2025

Igm biosciences officer sells shares worth $2,092 - Investing.com India

Mar 18, 2025

Igm biosciences officer sells shares worth $2,092 By Investing.com - Investing.com Australia

Mar 18, 2025

IGM Biosciences stock plunges to 52-week low at $1.17 By Investing.com - Investing.com Australia

Mar 18, 2025

Mar 17, 2025

IGM Biosciences stock plunges to 52-week low at $1.17 - Investing.com India

Mar 17, 2025

Mar 08, 2025

IGM Biosciences Faces Uncertainty Amid Cash Preservation and Restructuring Efforts - TipRanks

Mar 08, 2025

Mar 07, 2025

IGM Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 07, 2025

Mar 05, 2025

Contrasting IGM Biosciences (NASDAQ:IGMS) and Gyre Therapeutics (NASDAQ:GYRE) - Defense World

Mar 05, 2025

Mar 04, 2025

IGM Biosciences stock plunges to 52-week low of $1.25 By Investing.com - Investing.com Australia

Mar 04, 2025

Mar 03, 2025

IGM Biosciences stock plunges to 52-week low of $1.25 - Investing.com India

Mar 03, 2025

IGM Biosciences Inc expected to post a loss of 74 cents a shareEarnings Preview - TradingView

Mar 03, 2025

Mar 02, 2025

IGM Biosciences (IGMS) Projected to Post Quarterly Earnings on Thursday - MarketBeat

Mar 02, 2025

Mar 01, 2025